ditions, hay fever and head colds; and for providing benefits to the bladder, kidneys, and related parts.

DISPOSITION: 12–18–59. The defendant having consented, the court entered a decree of permanent injunction enjoining and restraining the defendant from making or causing to be made any oral or written representations for the use of the article in the prevention or cure of any disease, condition, or infection of any kind which was not stated in the labeling of the article, while such article was held for sale after shipment in interstate commerce.

DRUGS ACTIONABLE BECAUSE OF DEVIATION FROM OFFICIAL OR OWN STANDARDS

6388. Sulfapyridine sodium powder (2 seizure actions). (F.D.C. Nos. 44699, 44700. S. Nos. 41–268/70 R.)

QUANTITY: 1 100-lb. drum, 8 1-lb. btls., and 1 25-lb. drum, at San Francisco, Calif.

SHIPPED: The article was shipped in bulk, on 10–8–58, from New York, N.Y., by Fine Chemical Co.

LABEL IN PART: (Drum) "Sodium Sulfapyridine N.F.X. For Manufacturing Use Only Fine Chemical Company, New York, N.Y."; (btl.) "Sulfapyridine Sodium N.F. Powder (Not Sterile) Trico Pharmaceutical Co. Oregon City–San Francisco–Los Angeles"; and (drum) "Sulfapyridine Sodium N.F. Powder Not Sterile Trico Pharmaceutical Co."

RESULTS OF INVESTIGATION: A portion of the bulk drug was repacked into 8 1-lb. bottles and 1 25-lb. drum after shipment. Analysis showed that the drug contained less than 99 percent sulfapyridine sodium.

LIBELED: 7–5–60, N. Dist. Calif.

CHARGE: 501(b)—when shipped, the strength of the article differed from the standard set forth in the National Formulary.

DISPOSITION: 8–24–60. Default—destruction.

6389. Tweltone solution. (F.D.C. No. 44756. S. No. 22–273 R.)

QUANTITY: 48 cartoned vials at Kansas City, Mo.

SHIPPED: 4–4–60, from Indianapolis, Ind., by Pitman-Moore Co.

LABEL IN PART: "10 cc. size Sterile Solution Tweltone Liver Folic Acid B_{12} * * * Pitman-Moore Company Div. of Allied Labs., Inc., Indianapolis. Sterility Test: 19464 Serial Lot No. 22159070."

RESULTS OF INVESTIGATION: Analysis showed that the article contained approximately 50 percent of the declared amount of vitamin B_{12}.

LIBELED: On or about 7–26–60, W. Dist. Mo.

CHARGE: 501(c)—when shipped, the strength of the article differed from that which it purported to possess; 502(a)—the label statement "Each cc. Represents: Vitamin B_{12} Activity * * * Equivalent to 10 Micrograms Cyanocobalamin, Fortified With Folic Acid, 10 mg. and Crystalline Vitamin B_{12} 50 Micrograms." was false and misleading.

DISPOSITION: 9–23–60. Default—destruction.

6390. Estrophen-B Regular Strength tablets. (F.D.C. No. 44732. S. No. 4–504 R.)

QUANTITY: 1 drum containing 18,000 tablets in bulk, 96 100-tablet btls., and 1 1,000-tablet btl., at Petersburg, Va.